Cellectis (CLLS) Profit After Tax Growth (5y) (2020 - 2026)

Cellectis (CLLS) Profit After Tax Growth (5y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Cellectis 285.50 Mn 99.83 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -2.97%
Dec 31, 2025 10.85%
Sep 30, 2025 15.07%
Jun 30, 2025 7.92%
Mar 31, 2025 -25.33%
Dec 31, 2024 16.48%
Sep 30, 2024 -3.42%
Jun 30, 2024 7.16%
Mar 31, 2024 18.31%
Dec 31, 2023 -9.90%
Sep 30, 2023 7.14%
Jun 30, 2023 -11.31%
Mar 31, 2023 -3.76%
Dec 31, 2022 0.11%
Sep 30, 2022 -1.45%
Jun 30, 2022 6.00%
Mar 31, 2022 -11.95%
Dec 31, 2021 -15.86%
Sep 30, 2021 -23.31%
Jun 30, 2021 -42.56%